HC Wainwright Has Bullish Forecast for FENC FY2026 Earnings

Adherex Technologies Inc. (NASDAQ:FENC – Free Report) – Equities researchers at HC Wainwright lifted their FY2026 EPS estimates for Adherex Technologies in a research report issued on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.34 per share for the year, up from their prior forecast of $0.21. HC Wainwright currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Adherex Technologies’ current full-year earnings is $0.36 per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2026 earnings at $0.15 EPS, Q1 2027 earnings at $0.17 EPS, Q2 2027 earnings at $0.23 EPS and FY2027 earnings at $1.00 EPS.

Other research analysts have also recently issued reports about the company. Wedbush upped their price objective on Adherex Technologies from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. B. Riley Financial restated a “buy” rating and issued a $19.00 target price (up from $18.00) on shares of Adherex Technologies in a research note on Monday, November 16th. Weiss Ratings raised Adherex Technologies from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, November 13th. Finally, Zacks Research raised shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $17.50.

View Our Latest Report on FENC

Adherex Technologies Price Performance

Adherex Technologies stock opened at $13.09 on Friday. The company’s 50 day simple moving average is $10.79 and its 200 day simple moving average is $9.50. The firm has a market capitalization of $460.99 million, a price-to-earnings ratio of 1,308.90 and a beta of 1.29. Adherex Technologies has a fifty-two week low of $5.65 and a fifty-two week high of $13.85.

Adherex Technologies (NASDAQ:FENC – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. The firm had revenue of $19.61 million for the quarter, compared to analysts’ expectations of $18.87 million. Adherex Technologies had a net margin of 2.52% and a return on equity of 8.96%.

Insider Activity

In other news, insider Pierre Sargis Sayad sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $12.18, for a total value of $146,160.00. Following the transaction, the insider owned 9,519 shares of the company’s stock, valued at approximately $115,941.42. This represents a 55.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert Andrade sold 75,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total transaction of $883,500.00. Following the transaction, the chief financial officer directly owned 217,675 shares in the company, valued at approximately $2,564,211.50. This represents a 25.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is owned by insiders.

Recent Adherex Technologies Headlines

Investors following FENC have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its earnings estimates across several periods, including FY2026 EPS to $0.34 from $0.21 and FY2027 EPS to $1.00 from $0.87. It also increased estimates for Q4 2026, Q1 2027 and Q2 2027. The analyst maintained a Buy rating and a $17 price target. Adherex Technologies stock price expected to rise, HC Wainwright analyst says
  • Positive Sentiment: HC Wainwright also lifted its Q3 and Q4 2027 EPS forecasts, adding to the improved earnings outlook. These higher projections may be supportive for FENC, but are analyst estimates and do not guarantee future results. Adherex Technologies analyst estimates

Adherex Technologies Company Profile

(Get Free Report)

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

Featured Stories

Earnings History and Estimates for Adherex Technologies (NASDAQ:FENC)

Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.